Oxaliplatin: A Review of Evolving Concepts

This publication has 100 references indexed in Scilit:

• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
  European Journal Of Cancer, 1999
• ‘Tomudex’ (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination
  European Journal Of Cancer, 1999
• Raltitrexed (‘Tomudex’) and oxaliplatin: an active out-patient regimen in malignant mesothelioma
  European Journal Of Cancer, 1999
• A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front line treatment in metastatic breast and non-small lung cancer (NSCLC): preliminary results
  European Journal Of Cancer, 1999
• A dose finding and toxicity study of the gemcitabine-oxaliplatin combination in patients with advanced solid tumors
  European Journal Of Cancer, 1999
• Oxaliplatin (L-OHP) + Tomudex (TOM) and levo-folinic acid (LFA) + 5-fluorouracil (5FU) every 2 weeks. A dose finding study in advanced colorectal carcinoma (ACC)
  European Journal Of Cancer, 1999
• Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors — Preliminary results of a phase I study
  European Journal Of Cancer, 1999
• NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) d(GpG) Intrastrand Cross-Link, the Major Adduct of the Anticancer Drug Cisplatin
  Biochemistry, 1998
• HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts 1 1Edited by M. Yaniv
  Journal of Molecular Biology, 1997
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
  Biochemical Pharmacology, 1996